Cryoablation Without Excision for Early-Stage Breast Cancer; ICE3 Trial Update on Ipsilateral Breast Tumor Recurrence (ASBRS)
Scientific Oral Presentation from ASBrS 2021. Of 194 eligible patients were treated with cryoablation, at a mean of 34.83 months (about 3 years) following treatment with the ProSense™ Cryoablation System, only 2.06% (4 patients) experienced cancer recurrence.
This study was aimed at evaluating the efficiency of cryoablation using liquid nitrogen in lung tissue by measuring the size and temperature distribution of the frozen area (ice ball) in gel and in the ex vivo pig lungs.
This study focused on evaluating local control and complications of cryoablation for T1N0M0 non-small cell lung cancer using liquid nitrogen.
This study evaluated cryoablation under ultrasound guidance in the office setting with liquid nitrogen system for patients with fibroadenoma.
The aim of the study was to evaluate cryoablation under ultrasound guidance in the office setting with liquid nitrogen system for patients with fibroadenoma.